Archives: Agenda

• Understand the reliance of both patients and doctors alike on online resources for trial and disease awareness.
• Learn about a new technology solution to search for digital opinion leaders sharing content online about the therapeutic area
• Discover how to identify and track Digital Opinion Leaders across all social and online platforms
• Plan how to engage Digital Opinion Leaders in trial awareness

• Key considerations for medical device clinical development program at different stages
• Optimize protocol design using data-driven approaches
• Leveraging policy advantages of Asia-Pacific to accelerate the program timeline
• Important factors when selecting a contract research organization (CRO) or other partners to manage a successful medical device study

• Biopharma has historically focused on achieving regulatory approval for value creation
• Asset valuations at the time of licensing or sale can be increased by expanding research plans to address non-regulatory stakeholders
• At the same time, new innovations in R&D productivity can lower the cost of trials while better managing risks of trial success

This session will explore how the ICF can become a patient engagement tool.

• How do potential participants view consent forms?
• Changes to make the consent form to be more engaging.
• Practical tips for changing your consent template.
• Challenges that exist for implementing a different type of consent form.

• Future-proofing supply chains to endure greater long-term sustainability responsibilities
• Adhering to sustainable practices without adding cost and risk to already tight budgets
• Operational implications of striving for more sustainable trial design
• Collaborating with supplier ecosystems to drive sustainability goals
• Sharing best practice for circular supply chain strategies and creating win-win business opportunities

Chair: Joshua Cox, Vice President of Clinical Data & Analytics Capabilities, Eli Lilly and Company

• How can sponsors and service providers start using guidance in totality instead of in silos?
• Overcoming the lack in consistency of regulations between regions and countries
• Collaborative ways to render it easier for regulators to accept multiregional trial data
• Developing shared expectations for trial conduct, acceptability of endpoints and data transparency

Chair: Revati Tatake, Global Head of Pharma Research, Analysis and Competitive Intelligence, GlobalData

• Building a partnership reciprocity between sites and sponsors to reduce discord and ensure sites are confident enough to succeed
• Is it fair to place the shortcomings of trial success on site performance?
• Developing an integrated strategic global site engagement model to transform site experience
• Enabling innovative approaches to drug development and delivering new treatments to patients faster
• Equipping sites with a clear and well-defined protocols to be able to best respond to sponsor needs

• In such sensitive environments, can you really trust AI to ensure the
• total compliance of your clinical trial?
• How can we overcome data shortages in smaller trials for the necessary algorithms
• Tangible use cases for successful implementation of AI in clinical trial data management
• Ascertaining an attractive ROI with AI investment
• Redefining biostatistics reporting as we traditionally know it with AI tools
• Unlocking new endpoints

• Feasibility figures true to delivery
• Regulatory dynamics for strategic advantages
• Collaborate with patients and physicians to enhance access to innovative therapies
• New study designs that accelerate development programs